Corporate

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation.

Currently, the company’s product Perfadex® has a market share of approximately 90 percent in the traditional preservation of lungs for transplantation. The company’s products XPS™ and STEEN Solution™ for warm perfusion have regulatory approval in all major markets, and are the only products for warm perfusion of marginal lungs to have received regulatory approval from the FDA (approved under Humanitarian Device Exemption).

XVIVO Perfusion employs approximately 40 people at its headquarters in Gothenburg, Sweden, its office in Lund, Sweden, and its office for North & South America in Denver, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO.